These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28584971)

  • 1. F-18 FDG and F-18 Tau PET in posterior cortical atrophy.
    Tripathi M; Bansal A; Baghel V; Kumar P; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1779-1780. PubMed ID: 28584971
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
    Xia C; Makaretz SJ; Caso C; McGinnis S; Gomperts SN; Sepulcre J; Gomez-Isla T; Hyman BT; Schultz A; Vasdev N; Johnson KA; Dickerson BC
    JAMA Neurol; 2017 Apr; 74(4):427-436. PubMed ID: 28241163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.
    Spehl TS; Hellwig S; Amtage F; Weiller C; Bormann T; Weber WA; Hüll M; Meyer PT; Frings L
    J Neuroimaging; 2015; 25(2):281-288. PubMed ID: 24593796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain [18F]FDG PET-CT imaging in posterior cortical atrophy.
    DE Brito MH; Zampieri PF; Coutinho AM; Brucki SMD
    Arq Neuropsiquiatr; 2019; 77(10):752-753. PubMed ID: 31664353
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Vanhoutte M; Semah F; Rollin Sillaire A; Jaillard A; Petyt G; Kuchcinski G; Maureille A; Delbeuck X; Fahmi R; Pasquier F; Lopes R
    Neurobiol Aging; 2017 Nov; 59():184-196. PubMed ID: 28882421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease.
    Yakushev I; Bartenstein P; Siessmeier T; Hiemke C; Scheurich A; Lotz J; Fellgiebel A; Müller MJ
    Dement Geriatr Cogn Disord; 2010; 30(3):245-53. PubMed ID: 20847555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR, (18)F-FDG, and (18)F-AV45 PET correlate with AD PSEN1 original phenotype.
    Saint-Aubert L; Payoux P; Hannequin D; Barbeau EJ; Campion D; Delisle MB; Tafani M; Viallard G; Péran P; Puel M; Chollet F; Demonet JF; Pariente J
    Alzheimer Dis Assoc Disord; 2013; 27(1):91-4. PubMed ID: 22517194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy.
    Ossenkoppele R; Schonhaut DR; Baker SL; O'Neil JP; Janabi M; Ghosh PM; Santos M; Miller ZA; Bettcher BM; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Ann Neurol; 2015 Feb; 77(2):338-42. PubMed ID: 25448043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
    Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain changes within the visuo-spatial attentional network in posterior cortical atrophy.
    Cerami C; Crespi C; Della Rosa PA; Dodich A; Marcone A; Magnani G; Coppi E; Falini A; Cappa SF; Perani D
    J Alzheimers Dis; 2015; 43(2):385-95. PubMed ID: 25114070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
    Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
    Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
    J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias.
    Koeppe RA; Gilman S; Joshi A; Liu S; Little R; Junck L; Heumann M; Frey KA; Albin RL
    J Nucl Med; 2005 Jun; 46(6):936-44. PubMed ID: 15937303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
    Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
    J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Tau Imaging More Than Just Upside-Down
    van Eimeren T; Bischof GN; Drzezga A
    J Nucl Med; 2017 Sep; 58(9):1357-1359. PubMed ID: 28490468
    [No Abstract]   [Full Text] [Related]  

  • 18. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.
    McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB
    CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.
    Kawachi T; Ishii K; Sakamoto S; Sasaki M; Mori T; Yamashita F; Matsuda H; Mori E
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):801-9. PubMed ID: 16550383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.